Back to search

Article

Multi-omics analysis of AML cells treated with azacitidine reveals highly variable cell surface proteome remodeling

2018-07-14

Abstract excerpt

Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are diseases of abnormal hematopoietic differentiation with aberrant epigenetic alterations. Azacitidine (AZA) is a DNA methyltransferase inhibitor (DNMTi) widely used to treat MDS and AML, yet the impact of AZA on the cell surface proteome has not been defined. To identify potential therapeutic targets for use in combination with AZA in AML patients...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
86fb48e2-5dc3-5544-b51f-31d317faa864
DOI
10.1101/369322
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Multi-omics analysis of AML cells treated with azacitidine reveals highly variable cell surface proteome remodelingDOI 10.1101/369322
Multiomics of azacitidine-treated AML cells reveals variable and convergent targets that remodel the cell-surface proteomeSemantic proximity
mRNA m5C Alteration in Azacitidine Demethylation Treatment of Acute Myeloid LeukemiaSemantic proximity
Multi-omics reveals azacitidine partially restores the hematopoiesis-supportive functions in mesenchymal stromal cells from patients with chronic myelomonocytic leukemiaSemantic proximity
Autophagy degrades immunogenic endogenous retroelements induced by 5-azacytidine in acute myeloid leukemiaSemantic proximity
AZA-MS: a novel multiparameter mass spectrometry method to determine the intracellular dynamics of azacitidine therapy in vivoSemantic proximity
Dynamic heterogeneity towards drug resistance in AML cells is primarily driven by epigenomic mechanism unveiled by multi-omics analysisSemantic proximity
Proteomic subtypes enrich current acute myeloid leukemia nomenclature and reflect intrinsic pathogenesis alongside agingSemantic proximity
Proteomic and phosphoproteomic landscapes of acute myeloid leukemia.Semantic proximity
Hypomethylating agents induce epigenetic and transcriptional heterogeneity with implications for AML cell self-renewalSemantic proximity
Direct modulation of the bone marrow mesenchymal stromal cell compartment by azacitidine enhances healthy hematopoiesisSemantic proximity
Clinical implications of genome-wide DNA methylation studies in acute myeloid leukemiaSemantic proximity
Integrative Genomics Identifies the Molecular Basis of Resistance to Azacitidine Therapy in Myelodysplastic SyndromesSemantic proximity
Select a neighboring publication to make it the new centre.